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Case Report
Peripartum Cardiomyopathy Reached Progressive 
Recovery Despites Poor Initial Ejection Fraction
  
Christian Sunur1, Bambang Hermawan1, Dorothea Apitule2
Peripartum cardiomyopathy (PPCM) is a pregnancy-associated, idiopathic 
cardiomyopathy secondary to marked left ventricular dysfunction, which 
manifests between the last month of pregnancy and the first five months 
postpartum. While it is relatively rare, PPCM is associated with significant 
morbidity and can be fatal. Its diagnosis is often delayed because its symp-
toms closely resemble those within the normal spectrum of pregnancy and 
the postpartum period. When PPCM is misdiagnosed or is not diagnosed 
in time, the consequences for patients could be deadly. We present a 
rare case which was first misdiagnosed but had a continuous progressive 
recovery of LV systolic function (LVSF) within five years after it was finally 
diagnosed and treated.
A 23 year-old female, P1A0, 8-weeks postpartum, was admitted to the 
emergency unit of our hospital because of dyspnea and fatigue, which de-
veloped three days after the delivery of her child. A week prior to delivery 
she was admitted to the hospital due to coughing, proteinuria and edema of 
her lower extremities. She was then diagnosed with severe preeclampsia. 
The patient, however, refused the administration of Magnesium-sulfate 
as a therapy because of personal reasons. 48 hours later, the patient was 
induced with oxytocin and she delivered a living female infant via vaginal 
delivery with no labor complications and was later discharged. Three days 
after delivery, the patient complained about having shortness of breath and 
fatigue. She went to a general practitioner who thought her symptoms were 
normal after a delivery. Two months later she went to an obstetric clinic for a 
check-up and was referred to the cardiology unit at our hospital. She stated 
that for the past two months, she had been experiencing symptoms such as 
exhaustion, palpitations, an inability to lay flat, decreased exercise tolerance 
and severe dyspnea. 
PPCM is a rare but potentially lethal disease that remains a challenge to 
diagnose, prognosticate, and treat. It is increasingly recognized that the 
condition is often diagnosed late which may indicate a poor prognosis. 
However, there are cases in which the initial severity of left ventricular 
dysfunction or dilatation is not necessarily predictive for long-term func-
tional outcome.
(J Kardiol Indones. 2016;37:90-7)
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Laporan Kasus
Kardiomiopati peripartum (PPCM) merupakan suatu keadaan kardiomiopati idiopatik yang berhubungan dengan kehamilan. 
Penyakit ini bermanifestasi sebagai gagal jantung akibat disfungsi ventrikel kiri dan dapat terjadi pada satu bulan terakhir 
kehamilan sampai dengan lima bulan setelah melahirkan. Meskipun prevalensinya tergolong rendah, PPCM dikaitkan dengan 
angka morbiditas yang signifikan dan dapat berakibat fatal. Diagnosis sering tertunda karena gejalanya serupa dengan gejala yang 
muncul pada kehamilan normal dan periode setelah melahirkan. Ketika PPCM salah atau terlambat terdiagnosis, konsekuensinya 
dapat berakibat fatal. Kami menyajikan sebuah kasus yang jarang terjadi ketika PPCM terlambat terdiagnosis namun mengalami 
pemulihan progresif dan terus menunjukkan perbaikan fungsi sistolik ventrikel kiri dalam waktu lima tahun.
Seorang wanita berusia 23 tahun, P1A0, 8 minggu pospartum, diterima di Unit Gawat Darurat karena dispnea dan rasa lelah 
yang dirasakannya tiga hari setelah melahirkan. Seminggu sebelum melahirkan, pasien dirawat di rumah sakit karena batuk, 
proteinuria, dan edema pada anggota gerak tubuh bagian bawah. Pasien kemudian didiagnosis preeklampsia berat. Empat 
puluh delapan jam kemudian pasien melahirkan bayi perempuan dengan persalinan normal tanpa komplikasi setelah diinduksi 
dengan oksitosin dan diperbolehkan kembali ke rumah. Tiga hari setelah melahirkan, pasien mengeluhkan sesak napas dan rasa 
lelah. Pasien memeriksakan diri ke dokter umum yang menganggap bahwa gejala tersebut normal dialami setelah melahirkan. 
Dua bulan kemudian pasien melakukan pemeriksaan di klinik bersalin dan dirujuk kepada unit kardiologi dengan keluhan 
kelelahan, palpitasi, tidak bisa berbaring telentang, batas toleransi rendah terhadap kegiatan fisik, dan dispnea berat. 
Kardiomiopati peripartum adalah penyakit yang jarang ditemukan namun berpotensi fatal. Penyakit ini sulit terdiagnosis, 
terprognosis, dan diobati. Sering kali penyakit ini terlambat didiagnosis yang bisa mengindikasikan prognosis buruk. Meskipun 
demikian, ada kasus-kasus ketika tingkat keparahan awal disfungsi atau dilatasi ventrikel kiri belum tentu bisa memprediksi 
hasil jangka panjang. 
(J Kardiol Indones. 2016;37:90-7)
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Introduction
Peripartum cardiomyopathy (PPCM) is a preg-nancy-associated, idiopathic cardio myopathy secondary to marked left ventricular dysfunc-tion, which manifests between the last month 
of pregnancy and the first five months postpartum. 
While it is relatively rare, PPCM is associated with 
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normal first and second heart sounds. No significant 
cardiac murmurs were detected. Vesicular breathing in 
both lungs with significant bilateral basal crackles was 
detected. Other physical findings include ascites and 
edema of the lower extremities.
Initial laboratory results were as follows: white 
blood cells=7.7x103/mm3; hemoglobin=10.0 g/dL; 
hematocrit=30.5%; platelets=153x10 103/mm3; 
albumin=2.9 g/dL; aspartate aminotransferase=29 
U/L; alanine aminotransferase=47 U/L; serum urea 
nitrogen=17 mg/dL; creatinine=0.81 mg/dL. The 
electrocardiogram showed Sinus Tachycardia of 123 
beats/minute. Chest X-ray showed a cardiomegaly 
with increased vascular congestion, bilaterally. Initial 
2D Transthoracic Echocardiography (TTE) showed 
General hypokinetic heart, Right and Left ventricle 
failure with poor left ventricular ejection fraction 
(LVEF 14.2%). The patient was hospitalized for 
further treatment in the Intensive Care Unit.
Treatment of PPCM includes O2 therapy 3 l/min 
through nasal cannula, albumin correction with extra 
IV furosemide and oral potassium slow release, with 
maintenance furosemide dose of 20 mg/day, warfarin 
2 mg/OD, Angiotensin Converting Enzyme Inhibitors 
(Captopril) 6.25 mg TDS, Digoxin 0.125 mg/BID, 
and Coenzyme Q 25 mg/BID.
She was treated in the Intensive Care Unit for 
three days. During the treatment, the pulmonary 
edema regressed and the patient was discharged after 
one week from the hospital for out-patient treatment 
of heart failure. The patient was also advised against 
subsequent pregnancies. During the follow-up there 
was a continuous improvement of left ventricle 
dimensions and function. 
Six months later, repeated 2D TTE showed 
normokinetic, normal-sized cardiac cavities, normalized 
diastolic and improved systolic function with LVEF 
of 53.1%. She was treated with Mineralocorticoid 
receptor Antagonists (Spironolactone) 12.5 mg 
OD, Angiotensin Converting Enzyme Inhibitors 
(Captopril) 6.25 mg TDS, B-blocker (Bisoprolol) 
1.25 mg OD and Coenzyme Q 25mg/BID. Digoxin, 
warfarin and furosemide were all discontinued. The 
patient was then scheduled for monthly follow-ups 
to reassess the cardiac function. After five years of 
routine follow-ups, repeated echocardiography showed 
normal-sized cardiac cavities, fully recovered with 
LVEF of 71% with normal cardiac valves function 
as shown by Table 1 and Figure 1-4, the patient was 
then taken off any treatment regimes.
significant morbidity and can be fatal. Its diagnosis is 
often delayed because its symptoms closely resemble 
those within the normal spectrum of pregnancy and 
the postpartum period. When PPCM is misdiagnosed 
or is not diagnosed in time, the consequences for pa-
tients could be deadly. We present a rare case which was 
first misdiagnosed but had a continuous progressive 
recovery of LV systolic function (LVSF) within five 
years after it was finally diagnosed and treated.
Case Illustration
A 23 year-old female, P1A0, 8-weeks postpartum, was 
admitted to the emergency unit of our hospital because 
of dyspnea and fatigue, which developed three days 
after the delivery of her child. A week prior to delivery 
she was admitted to the hospital due to coughing, 
proteinuria and edema of her lower extremities. 
She was then diagnosed with severe preeclampsia. 
The patient, however, refused the administration of 
Magnesium-sulfate as a therapy because of personal 
reasons. Forty eight hours later, the patient was induced 
with oxytocin and she delivered a living female infant 
via vaginal delivery with no labor complications and 
was later discharged. Three days after delivery, the 
patient complained about having shortness of breath 
and fatigue. She went to a general practitioner who 
thought her symptoms were normal after a delivery. 
Two months later she went to an obstetric clinic for a 
check-up and was referred to the cardiology unit at our 
hospital. She stated that for the past two months, she 
had been experiencing symptoms such as exhaustion, 
palpitations, an inability to lay flat, decreased exercise 
tolerance and severe dyspnea. The patient also 
complained of lower extremity edema. The patient 
denied ever having any heart problems before and was 
never diagnosed with any heart abnormalities nor had 
any family history of heart disease. The patient had 
regular antenatal care (ANC) with an OB-GYN, with 
data as follows: body weight=43 kg, height=152 cm, 
Body Mass Index (BMI)=18.6 kg/m2, blood pressure 
(BP)=110/70, heart rate (HR)=82 beats/minute. 
The patient’s body weight during 38th week of the 
pregnancy was 58 kg, with a BMI of 25.1 kg/m2.
Initial vital signs were a BP of 118/78 mmHg, HR of 
120 beats/minute, respiratory rate (RR) 28 rates/minute, 
temperature of 36.6oC, and an oxygen saturation of 
97%. Upon physical examination she had an apparent 
jugular venous distension. Cardiac auscultation showed 
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Discussion
Peripartum Cardiomyopathy (PPCM) is an uncom-
mon disorder associated with pregnancy in which the 
heart dilates and weakens, leading to symptoms of 
heart failure. The incidence has been fully agreed upon 
but it estimated to be 0.025% to 0.03%, i.e. (1/4000) 
to (1/3000) births respectively.1 PPCM may be difficult 
to diagnose because symptoms of heart failure can 
mimic those of pregnancy. Affected women may 
recover normal heart function, stabilize on medicines, 
or progress to severe heart failure requiring mechanical 
support or heart transplantation. Even when the heart 
recovers, another pregnancy may be associated with a 
risk of recurrent heart failure.2 This disorder carries a 
high mortality rate, since a misdiagnosis or a delayed 
diagnosis could consequently lead to death. Therefore, 
reaching a proper diagnosis is the initial challenge in 
caring for patients with PPCM.3
Risk factors that are associated with PPCM include 
advanced maternal age, multiparity, obesity, multi-fetal 
pregnancy, hypertension (chronic, pregnancy induced, 
or preeclampsia), low socioeconomic status and African 
American race.4-10 
The underlying cause of PPCM remains unknown. 
A number of proposed mechanisms include: genetic, 
viral myocarditis, abnormal immune response, 
hemodynamic response to pregnancy, hormonal 
abnormalities, and malnutrition.2 However, none has 
emerged as a convincing single etiology. This may be 
because PPCM represents a heterogeneous group of 
disease process with a multifactorial etiology.10,11 
Classic heart failure symptoms include dyspnea, 
dyspnea on exertion, lower extremity edema, and 
fatigue, and these are often presenting symptoms. Un-
fortunately, these symptoms can be indistinguishable 
from symptoms common in late pregnancy and the 
postpartum period, making the diagnosis challenging 
and often missed, as shown by our case report.12,13
Physical exam findings in PPCM may reveal signs 
of volume overload such as pulmonary rales, increased 
Table 1. Selected 2D TTE result
12 July 2010 17 January 2011 25 February 2016




Cardiac cavities LVE and RAE Normal-sized cardiac cavities Normal-sized cardiac cavities
Systolic and Diastolic Func-
tion
Systolic and Diastolic dysfunc-
tion 
Improvement Systolic and 
diastolic function
Normal systolic and diastolic 
function
LVEF 14.2% 53.8% 71%
Fractional shortening 6.4% 28.1 % 40.26%
LVEDD 56.1 mm 53.8 mm 49.8 mm
LVESD 52.5 mm 38.7 mm 29.7 mm
Valve MR mild with MVP(AML)
TR severe
PR Moderate





* LVE: left-ventricular enlargement, RAE: right atrial enlargement, LVEF: left-ventricular ejection fraction, LVEDD: left-ventricular end-diastolic 
diameter, LVESD: left-ventricular end-systolic diameter, MR: mitral regurgitation, AR: aortic regurgitation, TR: tricuspid regurgitation, PR: pul-
monic regurgitation, MVP: mitral valve prolapse, AML: anterior mitral leaflet.
Figure 1. Improved LVEF and FS over course of treatment 
(in percentage)
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respiratory rate, tachycardia, pathologic S3 or S4 heart 
sounds, distended neck veins, and lower extremity 
edema.2 While there are no specific electrocardiography 
(ECG) findings that are particularly helpful in 
diagnosing PPCM.14 As can be seen in this case, 
symptoms such as these can make diagnosis of PPCM 
difficult because some patients with preeclampsia 
may experience dyspnea, fatigue, and lower extremity 
edema.[15]
The National Heart, Lung and Blood Institute 
(NHLBI) and the National Institutes of Health (NIH) 
in the U.S., published a diagnostic criteria for PPCM 
to direct more accurate research on epidemiology, 
pathophysiology, and outcomes. Current diagnosis 
of PPCM is based on the presence of four clinical 
criteria: (1) Development of heart failure (HF) in the 
last month of pregnancy or within five months after 
delivery; (2) Absence of an identifiable cause for HF; 
(3) Absence of recognizable heart disease prior to the 
last month of pregnancy; (4) Echocardiography (TTE) 
criteria of left ventricular systolic dysfunction (left 
ventricular ejection fraction, LVEF<45%), fractional 
shortening of<30%, or both.4 In this case, peripartum 
cardiomyopathy was diagnosed upon exclusion of 
other reasons for the heart failure, according to the 
diagnostic criteria of peripartum cardiomyopathy.
Treatment of PPCM is based on guidelines 
for standard HF treatment, including angiotensin 
converting enzyme (ACE) inhibitors, angiostensin 
receptor blockers (ARBs), beta-blockers, spironolac-
tone, digoxin, diuretics, vasodilators and inotropes 
if needed. The mainstays of treatment for acute 
decompensated PPCM include diuretics and renin 
angiotensin inhibiting agents for patients that are 
hemodynamically stable. Once stabilized, beta-
blockers, aldosterone-antagonists and additional 
therapies should be initiated and up-titrated as 
tolerated in the out-patient setting, particularly in the 
setting of persistent LV dysfunction.10 Although early 
improvement in EF (i.e. within the first 3-6 months) 
predicts a good outcome, some women will have slow, 
gradual improvement in EF over years.12
An important additional therapy that we considered 
for this patient is anticoagulation therapy. Considering 
that the patient is in a hypercoagulable state and 
the depressed systolic function caused by PPCM, 
she is at a higher risk for thrombus formation and 
thromboembolic events.5,13,20 Warfarin anticoagulation 
should be considered for prevention of morbidity or 
mortality from thromboembolism.13
Figure 2-4. Transthoracic echocardiography results from 
12 July 2010 – 25 February 2016
Images showing the echocardiography results taken during three 
separate routine follow-ups: 12 July 2010 (Figure 2), 17 January 2011 
(Figure 3) and 25 February 2016 (Figure 4). Short axis view shows an 
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Since the patient had a poor initial LV ejection 
fraction (<25%), she was also given counseling against 
subsequent pregnancies in order to avoid risk of 
recurrence of heart failure.13
Recently, a growing body of evidence has pointed 
to abnormal prolactin metabolism as crucial in the 
etiology of PPCM, and prolactin inhibition is being 
explored as a novel treatment for PPCM.12,14,16 
The basis for the use of Prolactin inhibition (e.g. 
Bromocriptine) in PPCM is based on the hypothesis 
that PPCM is originated by increased oxidative stress 
in the postpartum heart through the enhancement of 
the cathepsin D-mediated cleavage of prolactin into 
its 16-kDa subform. 16-kDa prolactin has angiostatic 
and proapoptotic properties, which in turn, promotes 
vasoconstriction, inhibits endothelial cell proliferation 
and migration, and favors myocardial micro-vascular 
injury.17 However, a larger scale study is still needed 
to confirm the efficiency of prolactin inhibitors as a 
component of a treatment regime for PPCM. Other 
alternatives, such as pentoxifylline and intravenous 
immunoglobulin, are also being studied as other 
possible treatments for PPCM.18,19
The decision of when to discontinue medications 
depends not only on left-ventricular function and 
structure, but also on lingering symptoms, as proposed 
by the European Society of Cardiology (ESC) 
guideline.10 Digoxin had been given since patient 
was discharged but then switched to beta-blocker 
after 6-months of out-patient care and the patient is 
clinically stable and no longer shows any symptoms of 
congestion. Warfarin was also discontinued after the 
risk of thrombus formation is no longer prominent 
due to the gradual and consistent improvement of left 
ventricular function. B-blocker and ACE-inhibitor 
were continued as essential treatment of PPCM, along 
with mineralocorticoid receptor antagonist (MRA), 
with expectation of fully restoring the LV structure, as 
the patient still had LV structural problem (Table 1).
Prognosis of PPCM is positively related to the 
recovery of ventricular function.3,20 Effective treatment 
helps women recover cardiac function and reduces 
morbidity and mortality.21 Thus, it is important 
that general practitioners to be familiar with PPCM 
and therefore consider it when diagnosing dyspneic 
patients to ensure prompt medical treatment for a 
potentially lethal condition.
A fractional shortening less than 20% and a left 
ventricular diastolic dimension of 6 cm or greater at the 
time of diagnosis are associated with a more than three-
fold higher risk for persistent cardiac dysfunction.22 
The correlation between a depressed ejection fraction 
(EF) at the time of diagnosis and worse outcomes has 
been supported by several studies.5,21,23,24 However, 
other researchers have found no correlation between 
initial left-ventricular ejection fraction (LVEF) and 
survival, or recovery of LV function.9,20,25,26 In our 
case report, with an initial LVEF 14.2%, our patient 
managed to reach a better prognosis than expected. 
Thus, the initial severity of left ventricular dysfunction 
or dilatation is not necessarily predictive for long-term 
functional outcome.20,27
Conclusion
PPCM is a rare but potentially lethal disease that re-
mains a challenge to diagnose, prognosticate, and treat. 
It is increasingly recognized that the condition is often 
diagnosed late which may indicate a poor prognosis. 
However, there are cases in which the initial severity of 
left ventricular dysfunction or dilatation is not necessar-
ily predictive for long-term functional outcome.
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